Skip to main content

Resistance acquisition to MDM2 inhibitors

Cinatl, Jindrich, Speidel, Daniel, Hardcastle, Ian, Michaelis, Martin (2014) Resistance acquisition to MDM2 inhibitors. Biochemical Society transactions, 42 (4). pp. 752-757. ISSN 1470-8752. (doi:10.1042/BST20140035) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided)

The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided. (Contact us about this Publication)
Official URL
http://dx.doi.org/10.1042/BST20140035

Abstract

Various experimental strategies aim to (re)activate p53 signalling in cancer cells. The most advanced clinically are small-molecule inhibitors of the autoregulatory interaction between p53 and MDM2 (murine double minute 2). Different MDM2 inhibitors are currently under investigation in clinical trials. As for other targeted anti-cancer therapy approaches, relatively rapid resistance acquisition may limit the clinical efficacy of MDM2 inhibitors. In particular, MDM2 inhibitors were shown to induce p53 mutations in experimental systems. In the present article, we summarize what is known about MDM2 inhibitors as anti-cancer drugs with a focus on the acquisition of resistance to these compounds.

Item Type: Article
DOI/Identification number: 10.1042/BST20140035
Uncontrolled keywords: acquired resistance, murine double minute 2 inhibitor (MDM2 inhibitor), p53 mutation, targeted therapy.
Subjects: R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculties > Sciences > School of Biosciences
Depositing User: Martin Michaelis
Date Deposited: 12 Sep 2014 17:31 UTC
Last Modified: 29 May 2019 13:04 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/42923 (The current URI for this page, for reference purposes)
  • Depositors only (login required):